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Cervical cancer is the fourth most common cancer in women. Although cure rates are high for early 
stage disease, clinical outcomes for advanced, metastatic, or recurrent disease remain poor. To change 
this panorama, a deeper understanding of cervical cancer biology and novel study models are needed. 
Immortalized human cancer cell lines such as HeLa constitute crucial scientific tools, but there are few 
other cervical cancer cell lines available, limiting our understanding of a disease known for its molecular 
heterogeneity. This study aimed to establish novel cervical cancer cell lines derived from Brazilian 
patients. We successfully established one (HCB-514) out of 35 cervical tumors biopsied. We confirmed 
the phenotype of HCB-514 by verifying its’ epithelial and tumor origin through cytokeratins, EpCAM 
and p16 staining. It was also HPV-16 positive. Whole-exome sequencing (WES) showed relevant somatic 
mutations in several genes including BRCA2, TGFBR1 and IRX2. A copy number variation (CNV) analysis 
by nanostring and WES revealed amplification of genes mainly related to kinases proteins involved in 
proliferation, migration and cell differentiation, such as EGFR, PIK3CA, and MAPK7. Overexpression 
of EGFR was confirmed by phospho RTK-array and validated by western blot analysis. Furthermore, 
the HCB-514 cell line was sensitive to cisplatin. In summary, this novel Brazilian cervical cancer cell line 
exhibits relevant key molecular features and constitutes a new biological model for pre-clinical studies.
Cervical cancer is a major public health problem worldwide, making it the fourth most common type of cancer 
among women. In 2018, there were 570,000 new cases reported and 311,000 related deaths1. Women between the 
ages of 50 and 60 years-old are most affected by cervical cancer2. Persistent infection of the basal layer of cervi-
cal epithelium with high-risk human papillomavirus (HPV), such as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
and 68, is considered the main risk factor for the development of cervical cancer precursors, known as cervical 
intraepithelial neoplasia (CIN 1, 2, and 3), and invasive cervical cancer3.
Cervical cancer can be histologically classified as squamous cell carcinoma (SCC), adenocarcinoma and aden-
osquamous carcinoma, with a prevalence of 77%, 17% and 6%, respectively4. Many efforts have being under-
taken to determine the molecular profile of this heterogeneous disease. Recently, The Cancer Genome Atlas 
(TCGA) integrated information from CNV, methylation, mRNA, and miRNA profiles. Through clustering, the 
TCGA revealed three molecular subtypes of cervical cancer: SCC keratin-high, SCC keratin-low and adenocarci-
noma. Differences observed in the three major subtypes included the enriched expression of some genes such as 
PIK3CA, ADH7 and SPRR3 in the SCC keratin-high compared with the SCC keratin-low cluster; more frequent 
CNVs including common EGFR amplifications in SCCs; a high number of aberrations in tumor-suppressor genes 
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related with TGF-β pathway in adenocarcinomas including SMAD4 and TGFBR2 deletions, and increased DNA 
methylation in adenocarcinomas4,5.
Cervical cancer treatment is based on the stage of disease. For early stage disease, surgery is the primary 
treatment modality, cure rates are high, and 5-year overall survival is up to 92%6. For advanced disease, which 
includes recurrent or metastatic disease, the mainstay of therapy is chemoradiation with a platinum-based agent 
and unfortunately, treatment responses are poor7. To improve outcomes for patients with advanced disease, recent 
findings on the molecular profile of this tumor type is valuable.
To facilitate the discovery of new antineoplastic agents, many research centers and teams have been carry-
ing out screenings with a multitude of compounds, testing them in in vitro models, using immortalized human 
cancer cell lines8. This approach provides controlled conditions to evaluate the efficacy of drugs, and enables the 
unrestricted availability of human source material. However, there is a very low number of cervical cancer cell 
lines commercially available in comparison with other tumors, such as breast and lung tumors, which currently 
provides a limited representation of known subtypes and tumor heterogeneity. Therefore, the aim of this study 
was to establish and to characterize a new human cervical tumor cell line derived from a Brazilian patient.
Results
Clinical characterization and establishment of a primary cell culture. From March 2016 to June 
2017, 35 cervical tumor biopsies were processed (Suppl. Table 1). Only one (2,9%) of the cell cultures, named 
HCB-514, survived for more than 12 months and continued to grow after several freeze-thaw cycles. This cell 
line was derived from a 30 year-old patient diagnosed with stage IIB squamous cell carcinoma of the cervix. The 
patient was treated with concurrent chemoradiation with cisplatin from October 10 to November 17, 2016, and 
was disease-free through her most recent follow-up appointment, on April 25, 2018. The cell culture HCB-514 
grew attached to the flask, with cells forming an irregular island pattern with a cobblestone morphology, char-
acteristic of epithelial cells (Fig. 1). When the cell line became confluent, cells were frozen in 5% DMSO in fetal 
bovine serum (FBS) solution in liquid nitrogen for further assays. After the fourth passage, immunophenotypic 
characterization was performed. The HCB-514 cell line presented stable outgrowing for more than 6 months, 
reaching 26 passages, and it was HPV-positive, supporting a spontaneous immortalization process. The cell line 
was negative for mycoplasma, and a short tandem repeat (STR) analysis showed that the HCB-514 cell line, tumor 
tissue and peripheral blood shared the same markers, confirming cell line identity (Table 1).
Figure 1. Representative images of immunocytochemistry of cervical cancer cell line HCB-514 (top images) 
and the fibroblast cells (HCB-535) (bottom images). All pictures were taken at 100x magnification.
Regions Blood Tumor HCB-514
Amelogenin X X X
CSF1PO 10,12 10,12 12
D13S317 9,11 9,11 9,11
D16S539 9 9 9
D5S818 10,12 10,12 10
D7S820 11,13 11,13 13
THO1 7,9 7,9 7,9
TPOX 8,12 8,12 8,12
WA 16 16 16
Table 1. STR profile of cell culture, blood and frozen tissue of the patient.
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Immunophenotypic characterization. Immunocytochemistry of HCB-514 showed strong cytokeratin 
expression, but no vimentin expression, similar to SiHa, indicating that HCB-514 is an epithelial cell line (Fig. 1). 
On the other hand, HCB-535 fibroblast presented the opposite staining pattern, with strong vimentin expression 
but no cytokeratin expression (Fig. 1). Furthermore, immunohistochemistry from HCB-514 cell block was in 
accordance with the expression pattern of formalin-fixed paraffin embedded (FFPE) tumor tissue taken in paral-
lel from the patient at the time of biopsy. Both HCB-514 and FFPE tumor tissue were positive for p40, a squamous 
cell marker, and p16, a marker for cervical cancer (Fig. 2), confirming its squamous cell origin.
In addition, flow cytometry analysis showed high expression of EpCAM in HCB-514, with 100% of cells stain-
ing positive. Expression of EpCAM was present in 92% of SiHa cells and in 19% of the fibroblast cell line (Fig. 3).
Doubling-time. The growth curve for HCB-514 during exponential cell growth showed a doubling time of 
18 h in 10% FBS media, and 24 h in 5% FBS media. To evaluate whether this growth was faster or slower than 
other cell lines largely used for in vitro assays, SiHa was also evaluated and showed a doubling-time of 17 h in 10% 
FBS media and 21 h in 5% FBS. Thus, the time was similar among cell lines, with a faster doubling-time in 10% 
than in 5% media (Fig. 4).
HPV status and genotyping. HPV infection is present in almost all cervical tumors, therefore we eval-
uated the presence of the virus in the HCB-514 cell line. For this purpose, GP5+/GP6+ primers were used to 
amplify the highly conserved region of the HPV L1 gene by PCR. The band correspondent to this region was 
found in HCB-514, confirming the presence of HPV (Suppl. Fig. 1a). To identify which high-risk HPV type was 
present, a genotyping test was performed with the COBAS® HPV assay, confirming HPV type 16. Furthermore, 
Figure 2. Representative immunohistochemistry images of HCB-514 cell block slices (top images) and the 
tumor patient tissue (bottom images) depicting expression of p16 (cervical cancer marker) and p40 (squamous 
cell carcinoma marker). All pictures were taken at 100x magnification.
Figure 3. Evaluation of epithelial cellular adhesion molecule (EpCAM) expression in HCB-514. HCB-514 
(left), SiHa (center) and HCB-535 (right) cell lines were stained with antibody anti-EpCAM and evaluated 
in flow cytometry. SiHa, and a fibroblast cell line (HCB-535) were used as positive and negative controls, 
respectively. Black graphs represent unstained cells; red graphs represent stained cells.
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to confirm that HPV16 infection was present, we evaluated and confirmed the presence of E6 oncoprotein, an 
important protein responsible for HPV oncogenicity (Suppl. Fig. 1b).
Furthermore, WES allowed us to determine whether the HPV genome integrated into host genomic DNA of 
HCB-514 and in primary tumor. The results showed two integration sites, one into the MICU2 and the other into 
CDH13 genes, the last being also found in the WES of patient’s primary tumor.
Moreover, it is hypothesized that HPV genetic variation co-evolves with hosts of certain ethnic groups, which 
influences disease development and outcome8. Therefore, to identify the variant of HPV in HCB-514 and in the 
primary cervical cancer, phylogenetic analysis was performed. Both the HCB-514 cell line and the patient’s pri-
mary tumor showed the presence of the sublineage HPV16 A1 (Suppl. Fig. 2).
HCB-514 and tumor mutational profile. The WES analysis of paired cell line/blood revealed 520 somatic 
mutations. The analysis of the most significant non-silent mutations identified 93 mutated genes (Suppl. Table 3), 
such as HPS-3, IRX2, XPO5, CBWD1, TGFBR1, CUBN, TRHDE, BRCA2, THBS1, TGM5, CCDC22, which were 
previously described as pathogenic, or likely pathogenic in tumors (Suppl. Table 3).
Regarding the analysis of paired primary tumor/blood, 863 mutations were found, with 68 non-silent muta-
tions identified (Suppl. Table 4). Among them, 18 mutations were shared with HCB-514 (Table 2), including 
mutations in the BRCA2, TGFBR1, CCDC22 and SHKBP1 genes.
Several studies have reinforced the putative impact of APOBEC family of cytidine deaminases enzymes in 
altered nucleotides found in cervical cancer9. Therefore, mutational signatures from cell line and tumor were 
analyzed. Both samples showed similar mutation signatures, with C to A and C to T being the most predominant 
(Suppl. Fig. 3).
The BRCA2 mutation (p.W2830*) identified was further confirmed by Sanger sequencing (Fig. 5).
Figure 4. Growth curves of HCB-514 obtained from real time impedance-based technology cell analyzer 
system (xCELLigence). Different media conditions were assessed. Data represent the mean of 3 independent 






1 228335177 GUK1 C T p.R129W Heterozygous
2 69049563 ARHGAP25 G A p.G431E Heterozygous
5 140793112 PCDHGA10 G A p.E124K Heterozygous
7 77408339 RSBN1L A C p.K799Q Heterozygous
9 101900171 TGFBR1 C T p.A202V Heterozygous
10 51130414 PARG G A p.L59F Heterozygous
12 99194813 ANKS1B C G p.E1053Q Heterozygous
12 109201563 SSH1 G A p.R193W Heterozygous
13 32945095 BRCA2 G A p.W2830* Heterozygous
15 39874463 THBS1 G A p.R46H Heterozygous
15 43545745 TGM5 G A p.R215W Heterozygous
19 41084418 SHKBP1 G A p.R129W Heterozygous
20 4163484 SMOX G A p.G431E Heterozygous
20 23066708 CD93 G A p.E124K Heterozygous
21 47421214 COL6A1 G C p.K799Q Heterozygous
22 17590484 IL17RA C G p.A202V Heterozygous
22 19213831 CLTCL1 C T p.L59F Heterozygous
X 49105196 CCDC22 G T p.E1053Q Heterozygous
Table 2. Somatic non-silent mutations found in both HCB-514 and tumor.
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Copy number variation. Nanostring analysis for CNV was performed for both the cell line and constitutive 
DNA. Among all evaluated genes, 44 somatic alterations were discovered, including 30 regions with amplifica-
tion, containing genes such as MYC, TP53, EGFR, TERT, AKT3, MAPK7, BIRC2, YAP1 and 14 losses, containing 
genes including KIT, RB1, BRCA2 and APC (Tables 3 and 4).
To expand the analysis beyond the 87 genes of the NanoString panel, CNV was also investigated from WES 
data. The WES showed 64 chromosomal regions harboring a large number of genes with CNV. There were 30 
amplified regions, with 9 of them presenting high amplification, harboring genes such as MYNC, ALK, PIK3CA, 
BIRC3, ERCC4 and PALB2 (Table 3). Deletions were found in 34 regions, harboring genes such as MLH1, 
PDGFRA, APC, MET and RB1. Homozygous deletions were found in 5 regions (Table 4).
Many of the amplified genes identified are related with PI3K-AKT and MAPK signaling pathways. Other 
altered regions harbored genes mostly related with the DNA repair process, apoptosis and transcriptional factors. 
Moreover, the cell line presented alterations in tyrosine-kinase receptors, such as EGFR and ALK amplification 
and PDGFRA and MET deletion.
Regarding the CNV present in patient’s primary tumor, the number of CNVs was reduced compared with the 
HCB-514 cell line, with 4 amplification regions and 10 deletion regions. Again, both primary tumor and cell line 
shared some of these alterations, such as MYCN and ALK amplification and PDGFRA, KIT, IL2, FBXW7, MET 
and ATM deletion (Suppl. Table 4). Figure 6 summarizes CNV in the HCB-514 cell line and primary tumor.
Phospho-RTK expression. The characterization of RTK expression in HCB-514 revealed basal protein lev-
els of activated EGFR and ROR2 (Fig. 7a, top). Upon EGF stimulation, the only new receptor activated was ALK 
(Fig. 7a, bottom). Activation of EGFR was also confirmed by the presence of phosphorylated EGFR in Western 
blot analysis (Fig. 7b), with 3.5-fold more expression in HCB-514 than in SiHa (Fig. 7c).
Response to Cisplatin. To evaluate the sensitivity of HCB-514 to the chemotherapeutic agent cisplatin, 
commonly used in clinical practice for cervical cancer treatment, HCB-514 was treated for 72 hours and a MTS 
assay was performed. The response to cisplatin was dose-dependent and the inhibitory concentration for 50% 
cells (IC50) value for HCB-514 was 3 ± 0.42 µM, while IC50 value for SiHa was 39 ± 4.07 µM, a 13-fold increase 
(Fig. 8).
Discussion
Cancer cell lines are unique tools for understanding biology and tumor response. At present, immortalized cer-
vical cancer cell lines available in major cell repositories, including ATCC or ECACC, represents only six cervical 
cancers (not considering HeLa-derived cell lines), not reflecting the whole spectrum of cervical cancer biological 
heterogeneity, neither representing patients from South America.
In the present study, we successfully established a cervical cancer cell line, HCB-514, out of 35 attempts - a 
successful rate of 3%. It is difficult to establish cervical cell lines, with success rates ranging from 11–30%, which 
may explain the reduced number of new cell lines9–12.
Not all mechanisms of continuous cell growth in vitro are known, but, at least for HPV-positive cervical can-
cers, the presence of papillomavirus E6/E7 expression is an important requirement12. Importantly, the HCB-514 
cell line was HPV-16 positive and expressed E6 oncoprotein. Moreover, in our cell line and respective primary 
tumor, we showed that HPV integrates into the CDH13 gene. This gene negatively regulates keratinocyte prolifer-
ation and has been reported as one of the integration-targeted cellular genes (ITGs) in cervical cancer13. Although 
the role of these ITGs in carcinogenesis is not completely understood, it is suggested that ITGs modulate the 
expression of nearby genes through a long-distance chromatin interaction mechanism13. In addition, we used 
phylogenetic analysis to confirm the HPV16 A1 variant in both HCB-514 and primary tumor. This variant has 
been correlated with a high risk of precancer and cancer in Caucasian women14.
The molecular characterization of the HCB-514 cell line showed mutations in important cancer-related genes, 
yet exhibited a distinct profile compared to the profile for cervical squamous cell carcinomas recently reported by 
TCGA4. One of the mutated genes, BRCA2, is a well-known hereditary breast cancer gene that encodes a protein 
related to DNA damage repair during homologous recombination15. Mutations in BRCA2 occur in approximately 
Figure 5. IGV image from the whole-exome sequencing (WES) result of BRCA2 gene (left) and 
electropherogram of exon 20 from BRCA2 gene that harbors mutation (G → A) (right).
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3% of cervical cancers according to the TCGA dataset www.cbioportal.org. Notably, there is limited knowledge 
of BRCA2 mutational status in cervical cancer, and current literature focuses on germline mutations and its role 
on non-HPV related cervical cancers, mostly associated with hereditary syndromes16,17. There are no functional 
studies about BRCA2 mutation in cervical cancer. Interestingly, the pathogenic p.W2830* BRCA2 mutation iden-
tified in HCB-514 has been identified in other cancers as a predictive marker for targeted therapies, such as PARP 
inhibitors; its role in cervical cancers remains unclear.
We also observed a mutation in the TGFBR1 gene, which encodes a receptor that acts on the TGF-β signaling 
pathway. This pathway is also related to the TGFBR2 gene, which is one of the most commonly mutated genes in 
cervical cancer4. When TGBR2 is activated by a TGF-β ligand, TGBR1, a serine/threonine kinase, is dimerized, 
leading to the cell cycle arrest of epithelial cells, control of mesenchymal cell proliferation and differentiation, and 
other cell processes related to growth suppression18. In this sense, TGF-β inhibitors, such as galunisertib, may 
emerge as a new approach for the treatment of cervical cancer in TGFBR1-mutated tumors19.
We also observed the presence of a mutation in the IRX2 gene. The IRX2 belongs to the iroquois homeobox 
gene family and encodes a transcription factor known to play multiple roles during embryo development20. In 
breast cancer, low expression of IRX2 has been observed and shown to be associated with the presence of dis-
seminated tumor cells21. In this line, cell lines edited to overexpress IRX2 exhibited lower cellular motility and 
reduced secretion of pro-metastatic chemokines20. Moreover, the methylation of the IRX2 promoter region has 
been correlated with pleural anthracosis disease in lung adenocarcinomas22. Controversially, in primary human 
osteosarcoma tissues, IRX2 expression was observed to be significantly increased in comparison with normal 
tissues, and was significantly associated with tumor progression and prognosis23. In vitro assays showed that IRX2 
Chromosome 
Region CNV Cytoband Cancer genes
chr1 Amplification p36.33; q32.1
chr1 High amplification q32.1 - q43 H3F3A, FH
chr1 Amplification q43 - q44 AKT3
chr2 High amplification p25.3 - p22.3 MYCN, C2orf44, NCOA1, DNMT3A, ALK
chr2 High amplification p22.3 - p21 EML4
chr2 Amplification p21 - q33.1 MSH2, MSH6, FBXO11, BCL11A, REL, XPO1, IGL@, TTL, PAX8, ERCC3, CHN1, HOXD13, HOXD11, NFE2L2, PMS1, SF3B1
chr2 Amplification q37.3
chr3 High amplification q11.1 - q26.1 TFG, CBLB, GATA2, RPN1, FOXL2, WWTR1, GMPS, MLF1
chr3 High amplification q26.1 - q29 EVI1, PIK3CA, SOX2, ETV5, EIF4A2, BCL6, LPP, DCUN1D1, PRKCI
chr3 High amplification q29 TFRC
chr5 Amplification p15.33 - p11 IL7R, LIFR, SKP2, TERT
chr6 Amplification q12
chr7 Amplification p22.3 - q11.21 CARD11, PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11, HOXA13, JAZF1, IKZF1, EGFR
chr8 Amplification p23.3 - q24.3
PCM1, WRN, WHSC1L1, FGFR1, HOOK3, TCEA1, PLAG1, 
CHCHD7, NCOA2, HEY1, COX6C, EXT1, MYC, NDRG1, RECQL4, 
C8orf33, C8orf4
chr9 Amplification q32
chr11 Amplification q12.3 - q13.4 MEN1, CCND1, ORAOV1, FADD
chr11 Amplification q13.4 - q22.1 NUMA1, PICALM, MAML2, GAB2, YAP1
chr11 High amplification q22.1 - q22.3 BIRC2, BIRC3
chr12 Amplification p13.33
chr12 Amplification q23.1 - q24.33 ALDH2, PTPN11, BCL7A
chr14 Amplification q11.1 - q32.33 BCL2L2, CCNB1IP1, TRA@, NKX2-1, NIN, KTN1, GPHN, TSHR, TRIP11, GOLGA5, DICER1, TCL6, TCL1A, BCL11B, AKT1, IGH@
chr15 Amplification q21.3 - q26.3 IGF1R, FLJ27352, TCF12, PML, NTRK3, IDH2, CRTC3, BLM
chr16 Amplification p13.3
chr16 High amplification p13.3 - p11.2 TSC2, CREBBP, CIITA, SOCS1, TNFRSF17, ERCC4, MYH11, PALB2, IL21R, FUS
chr17 Amplification p13.3 - q11.2 MAPK7, YWHAE, USP6, TP53, PER1, GAS7, MAP2K4, NF1, SUZ12
chr18 High amplification p11.31
chr18 Amplification p11.31 - p11.23
chr18 Amplification p11.1 - q23 DCC, ZNF521, SS18, MALT1, BCL2
chr19 Amplification p13.2
chr20 Amplification p13 - q13.33 BCL2L1, NCOA3, AURKA, ZNF217, EEF1A2, ASXL1, MAFB, TOP1, SDC4, GNAS, SS18L1
Table 3. Copy number amplification regions in HCB-514 cell line.
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upregulated MMP-9 and VEGF in a PI3K/AKT-dependent manner, and that knockdown of IRX2 in osteosar-
coma cell lines inhibited cell proliferation and invasion23,24.
Another gene of interest that was mutated in both the HCB-514 cells and patient’s tumor tissue was SHKBP1. 
Recently, SHKBP1 was identified in the cervical cancer TCGA, as a significantly mutated gene in this tumor type4. 
Overexpression of SHKBP1 in cell lines led to a strong delay in the degradation of EGFR upon EGF activation25. 
This process occurred due to competitive binding of SHKBP1 with protein c-Cbl, thereby interrupting the com-
plex c-Cbl-CIN85, which is responsible for endocytosis of EGFR containing vesicles25.
According to TCGA, an average of 88 somatic CNV was found per cervical tumor, including 26 amplifica-
tions, 37 deletions and 26 alterations in whole chromosome arms4. The HCB-514 cell line presented 30 amplifica-
tions and 34 deletions, showing 64 alterations in total. Among these CNVs, EGFR and YAP1 genes were amplified 
in the HCB-514 cell line. Both amplifications have already been described as recurrent in cervical cancer4. In 
addition, to confirm the biological impact of EGFR gene amplification we analyzed and observed EGFR protein 
phosphorylation in the HCB-514 cell line. Interestingly, blocking the EGFR tyrosine-kinase protein is an effective 
approach to treat specific types of tumors, including colorectal, head and neck and lung cancers26.
In cervical cancer, a phase II clinical study with EGFR inhibitor Erlotinib showed that administering it prior 
to receiving the standard of treatment (cisplatin concurrent with radiotherapy) was safe and showed significant 
antitumor activity27. In addition, a recent study demonstrated a promising effect of lapatinib (anti- EGFR and 
Chromosome 
Region Event Cytoband Cancer genes
chr1 Deletion p11.2 - q21.1
chr2 Deletion q33.1 - q37.3 CREB1, IDH1, ATIC, FEV, PAX3, ACSL3
chr3 Deletion p26.3 - p12.3 SRGAP3, FANCD2, VHL, PPARG, RAF1, XPC, MLH1, MYD88, CTNNB1, SETD2, BAP1, PBRM1, FHIT, MITF, FOXP1
chr3 Deletion q26.1
chr4 Deletion p16.3 - p16.1 FGFR3, WHSC1
chr4 Deletion p16.1 - q22.1 SLC34A2, PHOX2B, FIP1L1, PDGFRA, CHIC2, KIT, KDR
chr4 Homozygous deletion q22.1
chr4 Deletion q22.1 - q26 RAP1GDS1, TET2
chr4 Deletion q26 - q35.2 IL2, FBXW7
chr5 Deletion p15.33
chr5 Deletion q11.1 - q13.2 IL6ST, PIK3R1
chr5 Homozygous deletion q13.2
chr5 Deletion q13.2 - q31.3 APC
chr5 Deletion q31.3 - q35.3 PDGFRB, CD74, ITK, EBF1, RANBP17, TLX3, NPM1, NSD1
chr7 Deletion q11.21 - q22.1 SBDS, ELN, HIP1, AKAP9, CDK6
chr7 Homozygous deletion q22.1
chr7 Deletion q22.1 - q35 MET, SMO, CREB3L2, KIAA1549, BRAF
chr7 Deletion q35 - q36.3 EZH2, MLL3, SHH
chr9 Homozygous deletion p13.2 - p13.1
chr9 Deletion p13.1 - p12
chr9 Homozygous deletion p12 - p11.2




chr11 Deletion q22.3 - q25 ATM, DDX10, POU2AF1, SDHD, PAFAH1B2, PCSK7, MLL, DDX6, CBL, ARHGEF12, FLI1
chr13 Deletion q11 - q34 CDX2, FLT3, BRCA2, LHFP, LCP1, RB1, ERCC5, FOXO1, GPC5, IRS2
chr18 Deletion p11.32 - p11.31
chr18 Deletion p11.23 - p11.21
chr18 Deletion p11.21
chr19 Deletion q13.42
chr21 Deletion q11.2 - q22.12 OLIG2, RUNX1
chr21 Deletion q22.2 - q22.3 TMPRSS2, U2AF1
chrX Deletion q24
Table 4. Copy number deletion regions in HCB-514 cell line.
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HER-2), in HER-expressing cervical cancer cells by reducing the number and size of blood vessels and prevent-
ing increased HIF-1α levels28. Regarding YAP1, the protein encoded by YAP1 gene, it is negatively regulated 
by the Hippo signaling pathway, and its enhanced activity is believed to induce cell proliferation, migration 
and survival in several cancer types including cervical cancer29,30. Increased activity of YAP1 can occur after 
TGFα and amphiregulin inhibit the Hippo signaling via EGFR29. Furthermore, YAP1 seems to play a key role 
in TGF-β1-induced apoptosis and EMT through EGFR regulation30. In cervical cancer, YAP1 was amplified in 
the EMT cluster samples from TCGA data highlighting the potential role of this gene in EMT-related tumor 
progression4. However, more functional studies on YAP1 amplification need to be conducted to elucidate its role 
in cervical cancer.
Figure 6. Copy number variations from whole-exome sequencing (WES) of HCB-514 (left) and tumor (right) 
were compared with patient’s blood DNA. Amplifications are shown in red markers and deletions in blue 
markers.
Figure 7. (a) Phospho-RTK arrays of HCB-514 were done at basal conditions (up) and upon EGF-stimulation 
(down). Each RTK is represented in duplicate in the arrays (two spots side-by-side), and three pairs of phospho-
tyrosine positive controls are located in the corners of each array. (b) Western blot of EGFR phosphorylation, 
showing the different amount of phospho-EGFR and total EGFR compared to the SiHa cell line. Alpha-tubulin 
was used as endogenous control. (c) Quantification of phospho-EGFR normalized with total EGFR.
Figure 8. Cell viability of HCB-514 and SiHa after 72 h of cisplatin treatment. Results were obtained using the 
MTS assay. Data represent a mean of 3 independent experiments done in triplicate.
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Finally, we showed the sensitivity of HCB-514 to cisplatin, in line with the patient’s clinical response to cispla-
tin (with concurrent radiotherapy).
In conclusion, the molecular profile of the novel Brazilian cervical cancer cell line HCB-514 reveals disruption 
of several key cellular pathways, such as PI3K-AKT, MAPK signaling, DNA repair, apoptosis, transcriptional 
factors and RTK. This new HPV-16 positive cervical cancer cell line constitutes an important model to better 
understand the cancer biology of cervical cancer and offers an additional promising tool for cervical cancer 
pre-clinical studies.
Materials and Methods
Establishment of cervical cancer cell lines. Blood and tumor tissue samples were collected from partici-
pants with cervical cancer during routine visits in the Gynecologic Oncology Department of BCH after informed 
consent was obtained. The collected tumor tissue was maintained in PBS buffer in the refrigerator until process-
ing, which occurred before 24 hours. The sample was initially placed in a petri dish and fragmented with scalpels 
and incubated for 30 min at 37 °C in a 15 mL falcon containing 5 mL of an enzymatic solution (0.14% collagenase 
type I [Sigma, Brazil] and 0.01% DNase [2,000 kilounits/mg] [Sigma]) in RPMI 1640 as previously described31. 
Then, RPMI medium was supplemented with 1% penicillin and streptomycin (P/S; Sigma) and 10% fetal bovine 
serum (FBS; Sigma) was added to inactivate the enzyme. After centrifugation, the cell pellet was resuspended in 
FAD media32 adapted by Dr. Matias Melendez (personal communication), which was comprised by three parts 
of Dulbecco’s modified Eagle’s media (DMEM; Sigma) to one part Ham’s F12 media (F12; Sigma). The media was 
then supplemented with 1% P/S, 0.4 µg/mL hydrocortisone, 2.5 µg/mL insulin, 13 ng/mL liothyronine, 5 µg/mL 
transferrin, 2.5 µg/mL insulin and 0.1 µg/mL cholera enterotoxin and 5% FBS (all supplements were purchased 
from Sigma). Cells were maintained in a T25 flask at 37 °C, 5% CO2. One week after processing, the media was 
replaced and cell growth was monitored. Controlled trypsinizations were done to preferentially remove the con-
taminating fibroblasts. Afterwards, the culture media was replaced every 72 h and the cell culture was routinely 
subcultured once it was confluent. Stock vials were frozen in FBS+ 5% DMSO solution for storage in liquid nitro-
gen. All methods were performed in accordance with the relevant guidelines and regulations and were approved 
by the Ethics and Research Committee from Barretos Cancer Hospital (BCH) (985/2015 - CAAE 1,252,699).
Cell lines. For molecular and functional characterization, the immortalized cervical squamous cell carcinoma 
cell lines, SiHa, was kindly provided by Dr. Luisa Villa (INCT-HPV, Brazil) and a human short-term primary 
culture of lung fibroblast, named HCB-535, was obtained from BCH. SiHa was grown in DMEM media supple-
mented with 1% P/S and 10% FBS and HCB-535 in RPMI media supplemented with 1% P/S and 10% FBS.
Immunophenotypic characterization. To confirm cell origin, immunocytochemistry was performed 
with antibodies against vimentin (positive for fibroblasts) and cytokeratin (positive for epithelial cells). When 
cells reached the fourth passage, they were plated in a 24-well plate (5 × 105 in 3 DMEM:1 F12 media + 5% FBS) 
and, upon reaching 80% confluence, cells were fixed with 4% paraformaldehyde for 15 min, washed 3 times with 
PBS, permeabilized with Triton X-100 (0.1% in water) for 4 min and washed as described. Endogenous peroxidase 
activity was inhibited for 10 min with H2O2 (3% in methanol). Blockage for non-specific labeling was performed 
through incubation with 50 µL of the Ultra V Block reagent (Thermo Scientific detection kit) for 10 min and, 
after washes, primary antibodies cytokeratin AE1/AE3 (Dako, ready to use) or vimentin (Dako, ready to use), 
incubation was done for 60 min and then washed. A biotinylated goat polyvalent antibody incubation for 10 min 
was performed, followed by washing. Streptavidin peroxidase incubation was next performed for 10 min and 
washed. Afterwards, the DAB chromogen (ThermoFisher Scientific) was applied for 10 min for staining. Finally, 
hematoxylin was used for counterstaining and the cells were photographed with a photographic camera coupled 
to a microscope (Olympus). The immortalized cell line SiHa, a grade II squamous cell carcinoma and HPV-16 
positive, was used as a positive control for the cytokeratin and HCB-535 was used as positive control for vimentin.
The markers p40 (Biocare Medical, dilution 1:100) and p16 (Roche, Ventana Systems, ready to use), commonly 
used in the routine pathology for determination of cervical cancer histology subtype33, were evaluated by immu-
nohistochemistry in the cell block of the new cervical cancer cell line established in this work and in FFPE tumor 
tissue from the cervical cancer patient. Moreover, expression of EpCAM (CD326, BD Biosciences)34, another 
marker of cervical carcinoma cells, was analyzed in the HCB-514 cell line by flow cytometry. Briefly, 5 × 105 cells 
were harvested, washed twice in BSA 0,2% in DPBS (centrifugation between the washes was 1500 rpm for 5 min), 
then 10 µL of EpCAM PE-conjugate were added and incubated for 20 min. Afterwards, cells were washed and 
analyzed by flow cytometry (Accuri BD). SiHa was used as positive control for EpCAM expression and HCB-535 
was used as negative control.
Cell line doubling-time. Growth characteristics of the cell line were analyzed by doubling-time evaluation. 
Doubling-time was determined through real time impedance-based technology cell analyzer system (RTCA, 
xCELLigence, Roche), according to manufacturer’s instructions. Firstly, 5,000 cells were plated into E-plate 
(xCELLigence, Roche) and proliferation rate was evaluated for 72 h. The new cervical cancer was maintained in 
supplemented media above described in establishment section, with 5% FBS or 10% FBS. SiHa was maintained 
in DMEM 1% P/S and 5 or 10% FBS. This assay results in a cell index, which considers cell viability, cell number, 
morphology and adhesion. At the end of assay, a cell growth curve is produced and the doubling-time was cal-
culated from the selected interval, which is basically the interval selected when the cell index doubled inside the 
log-phase35.
DNA isolation. For molecular characterization, DNA was isolated from 1 × 106 tumor cell pellet in the 
sixth passage using silica column from Biopur Mini Spin Plus 250 Extraction kit (Biopur), as described by the 
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manufacturer. Blood total DNA was automatically isolated from buffy coat of patient through Mini Kit DNA and 
Qiasymphony instrument (both from Qiagen) at BCH Biobank Department, according to the manufacturer. This 
technology combines silica-based extraction with magnetic particles purification. The protocol Blood 200 with 
an elution volume of 50 µL was used. Tumor DNA was isolated from a biopsy sample obtained from the patient 
through the Mini Kit DNA and Qiasymphony instrument (QIAgen). For tumor-isolated DNA, macrodissection 
was performed by an experienced pathologist and up to 25 mg of the sample containing at least 60% tumor 
area and up to 20% necrosis area were fragmented and submitted to digestion and homogenization procedures, 
according to the manufacturer’s instructions. The protocol Tissue 200 with an elution volume of 50 µL was used.
All DNA samples were quantified by both NanoDrop® 2000 (Thermo Scientific) and Qubit® 2.0 Fluorometer 
(Life Technologies) and were then stored at −20 °C for further genetic analysis. Blood DNA was used as reference 
to distinguish somatic from germline mutations.
Assessment of human papilloma virus (HPV). The presence of HPV in HCB-514 cell line was evaluated 
by in house PCR using GP5+ and GP6+ primers, able to amplify a fragment of ~142 pb of the HPV conserved 
region L136. For this, it was used 5 µL of DNA extracted from HCB-514, 20 mM of Thris-HCl buffer (pH 8.4), 
50 mM KCl, 1.25 U of Platinum Taq DNA polymerase, 2 mM of MgCl2, 0.2 mM dNTP mix, 0.6 µM of each primer 
(GP5+ and GP6+). Amplifications were performed in the equipment Applied Biosystems GeneAmp PCR System 
2700 (Applied Biosystems) and the cycle was as described: 94 °C for 4 min followed by 40 cycles of 1 min at 94 °C, 
2 min at 40 °C, and 1 min 30 seg at 72 °C. Then, a cycle of 72 °C for 7 min and the PCR products were stored at 4 °C 
before electrophoresis on a 2% agarose gel. DNA HPV-positive was used as positive control and water was used 
as negative control. PCR reagents were pursued from Invitrogen.
Moreover, the COBAS® 4800 HPV System (Roche) was used for genotyping HPV, according with manufac-
turer’s instruction. This assay utilizes DNA target amplification through real time PCR to detect 14 high-risk 
HPVs in a single assay. It genotypes HPVs 16 and 18 and simultaneously detects other non-16 and 18 high-risk 
types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) as a pool result in cases of infection.
In addition, because E6 oncoprotein is required for the oncogenic transformation of HPV-infected cervical 
epithelial cells and the most common high-risk HPVs associated with cervical cancer are 16 and 18, the pres-
ence of their E6 oncoprotein was assessed through an immunochromatographic test, using OncoE6TM Cervical 
Test (Arbor Vita), according with manufacturer’s instructions. Briefly, the lysate of 1 × 106 HCB-514 cells was 
incubated with monoclonal antibodies to oncoprotein E6 of HPV types 16 and 18 conjugated with alkaline phos-
phatase. Then, using a nitrocellulose test strip, this mix migrates up the test strip and if the protein is present, it is 
possible to observe a purple line in the strip. The position of the line indicates if E6 is from HPV-16 or HPV-18.
Cell line authentication by short tandem repeat (STR) profiling analysis. The STR analysis was 
carried out in DNA from cell culture, FFPE tumor tissue and blood from the patient as previously described for 
authenticity confirmation37,38.
Whole exome sequencing (WES) analysis. The DNA from the HCB-514 cell line, the patient’s primary 
tumor and paired blood sample were used for WES, with input of 50 ng on the Illumina HiSeq2500 ™ System 
by a commercial company (Mendelics, São Paulo, Brazil). Sequence reads were aligned to the human reference 
genome build 37 (hs37d5-decoy) using BWA-MEM with Burrows–Wheeler Aligner version 0.7.10-r78939. 
Duplicate reads were marked with Picard-Tools 1.92 (http://broadinstitute.github.io/picard/). MuTect version 
1.1.4; (http://www.broadinstitute.org/cancer/cga/mutect) and Varscan240 were used to call somatic SNVs and 
indels in tumor-normal pairs, respectively. MuTect was run using default parameters with files from COSMIC 
version 54 and dbSNP version 132 included as input41,42. We used Ensembl Variant Effect Predictor (VEP)43 to 
annotate and determine functional consequences of tumor specific variants. The results from SIFT, Polyphen-2, 
ClinVar were considered. It was also excluded variants that were likely to be germline, i.e., listed in ESP6500 
(http://evs.gs.washington.edu/EVS/), 1000Genome or ExAC44,45. The candidate mutations were validated vis-
ually using the Integrated Genomics Viewer (IGV)46. Copy number abnormalities (CNA) were identified using 
Nexus Copy Number version 9.0 (BioDiscovery; El Segundo, CA; https://www.biodiscovery.com/products/
Nexus-Copy-Number) with default parameter for BAM ngCGH (matched) input with homozygous frequency 
threshold and value at 0.97 and 0.8 respectively, hemizygous loss threshold at −0.18, single copy gain at 0.18 and 
high copy gain at 0.6.
Mutational signature was defined using the package SomaticSignatures of Bioconductor Software, as described 
by Gehring et al.47.
Integration of HPV viral DNA into the human genome was performed through integration mode of the pro-
gram HPVDetector, as previously described48. The phylogenetic analysis of HPV sequence was performed using 
the fasta consensus sequences of HPV16 (one from tumor sample and the other from cell culture) obtained 
from deep sequencing and a group of HPV16 complete genome sequences retrieved from GenBank were aligned 
with Muscle49 and edited with Se-Al v2.0a11 (available at http://tree.bio.ed.ac.uk/software/sea/). Phylogenetic 
reconstructions were performed by maximum likelihood (ML) criterion using RAxML version 8.0.050. The best 
fit model used for the ML reconstruction was GTR + Γ model without partitions. Node support was evaluated 
using 1,000 bootstraps cycles.
BRCA2 Sanger sequencing. To validate the mutation identified in WES in BRCA2, the HCB-514 cell and 
patient’s blood DNAs were submitted to PCR amplification of BRCA2 exon 20, using Hot Start Taq enzyme 
(Qiagen), as described by Costa et al.51. After amplification, PCR products were purified with the ExoSap enzyme 
(USB Affymetrix), and submitted to sequencing protocol using BigDye Terminator v3.1 Cycle Sequencing 
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Kit (Applied Biosystems). Sequencing was performed in 3500 XL Genetic Analyzer (Applied Biosystems), as 
described by Fernandes et al.52.
Copy number variation analysis. HCB-514 chromosomal alterations were also analyzed by the 
Nanostring plataform, using the nCounter® v2 Cancer CN Assay panel (NanoString Technologies, Seattle, WA, 
USA). This panel counts the CNV of 87 involved genes commonly amplified or deleted in various cancers (www.
nanostring.com/products/CNV). As control, the genomic DNA from the HCB-514 patient’s peripheral blood was 
used. The DNA input was 600 ng for HCB-514, and 473 ng for peripheral blood.
The raw data was captured by the nSolverAnalysis Software v3.0® program (NanoString Technologies). For 
the normalization of the results, 54 probes were used for regions of the genome that do not usually present CNV. 
After the data normalization, the mean of the counts from the 3 probes per each gene was calculated and the 
number of copies per gene was calculated as previously described53,54.
Human-receptor tyrosine kinase (RTK) array and Western blot. To characterize HCB-514 protein 
expression, the Proteome Profiler Human Phospho-RTK Array Kit (#ARY001, R&DSystems) was used, according 
to the manufacturer’s instructions, and basal and epidermal growth factor (EGF)-stimulated protein expression 
were evaluated. Briefly, cells were grown in two T75 flask until confluence. Then, for EGFR stimulation, EGF 
diluted in 10 mL of free-serum media (final concentration 10 ng/mL) was firstly added to the cells and incu-
bated for 15 min. After, proteins were collected using lysis buffer (50 mM Tris pH7.6–8, 150 mM, NaCl, 5 mM 
EDTA, 1 mM Na3VO4, 10 mM NaF, 10 mM,sodium pyrophosphate, 1% NP-40, and protease cocktail inhibi-
tors) and 500 µg of protein lysates were incubated as previously described55. Membranes were revealed with ECL 
Western Blotting Detection Reagents (RPN2109, GE Healthcare) and the chemiluminescent signal was detected 
by ImageQuant™ LAS 4000 mini documentation system (GE Healthcare).
For Western blot, protein lysates were separated in 8% SDS-PAGE gel, transferred, incubated in 
phospho-EGFRY1068 (1:1000), EGFR (1:1000) or α-tubulin (1:2000) primary antibody and revealed, as detailed 
described by Silva-Oliveira et al.56. Antibodies were purchased from Cell Signaling company.
Viability evaluation. The cell viability of the HCB-514 cell line to cisplatin was evaluated by MTS assay 
as previously reported38. Briefly, 6,000 cells were plated in 96-wells, allowed to adhere, and then treated with a 
range from 0.01 to 8 µM of cisplatin (Sigma). After 72 h, the Cell Titer 96 Aqueous Cell Proliferation Assay (MTS 
reagent, Promega) was added and incubated for 3 h. Absorbance values were normalized with absorbance of 
DMSO 1%-treated cells and the IC50 (inhibitory concentration for 50% cells) was calculated through non-linear 
regression.
Statistical analysis. GraphPad Prism was used to determine IC50 in drug-response assays and to plot the cell 
index data from doubling-time assay and the relative protein expression from Western blot analysis.
Data Availability
Genetic data has been deposited at the European Genome-phenome Archive (EGA, http://wwwdev.ebi.ac.uk/
ega/), which is hosted by the EBI, under accession number EGAS00001003343.
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